Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep 9;8(9):e73653.
doi: 10.1371/journal.pone.0073653. eCollection 2013.

Muricholic acids inhibit Clostridium difficile spore germination and growth

Affiliations

Muricholic acids inhibit Clostridium difficile spore germination and growth

Michael B Francis et al. PLoS One. .

Abstract

Infections caused by Clostridium difficile have increased steadily over the past several years. While studies on C. difficile virulence and physiology have been hindered, in the past, by lack of genetic approaches and suitable animal models, newly developed technologies and animal models allow these processes to be studied in detail. One such advance is the generation of a mouse-model of C. difficile infection. The development of this system is a major step forward in analyzing the genetic requirements for colonization and infection. While important, it is equally as important in understanding what differences exist between mice and humans. One of these differences is the natural bile acid composition. Bile acid-mediated spore germination is an important step in C. difficile colonization. Mice produce several different bile acids that are not found in humans. These muricholic acids have the potential to impact C. difficile spore germination. Here we find that the three muricholic acids (α-muricholic acid, β-muricholic acid and ω-muricholic acid) inhibit C. difficile spore germination and can impact the growth of vegetative cells. These results highlight an important difference between humans and mice and may have an impact on C. difficile virulence in the mouse-model of C. difficile infection.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Structures of common muricholic acids.
The primary bile acids (cholic acid, chenodeoxycholic acid, α-muricholic acid and β-muricholic acid) are listed. Deoxycholic acid and ω-muricholic acid are secondary bile acids and are products of the normal microbiota.
Figure 2
Figure 2. α-muricholic acid inhibits germination by C. difficile UK1 spores.
(A) Germination of Clostridium difficile UK1 spores in complex medium supplemented with taurocholic acid (TA) or (B) medium supplemented with TA and 1 mM CDCA or (C) medium supplemented with TA and 1 mM α-muricholic acid. • 0 mM TA, ▪ 2 mM TA, ▴ 5 mM TA, ▾ 10 mM TA,♦ 20 mM TA or ○ 50 mM TA. (D) The inverse rate (1/v [sec/OD600]), versus the inverse taurocholate concentration (1/S [mM−1], was plotted. Apparent Km values for TA alone (•) and in the presence of α-muricholic acid (▪) were determined from the linear best fit.
Figure 3
Figure 3. α-muricholic acid inhibits germination by C. difficile M68 spores.
(A) Germination of Clostridium difficile M68 spores in complex medium supplemented with taurocholic acid (TA) or (B) medium supplemented with TA and 1 mM α-muricholic acid. • 0 mM TA, ▪ 2 mM TA, ▴ 5 mM TA, ▾ 10 mM TA,♦ 20 mM TA or ○ 50 mM TA. (C) The inverse rate (1/v [sec/OD600]), versus the inverse taurocholate concentration (1/S [mM−1], was plotted. Apparent Km values for TA alone (•) and in the presence of α-muricholic acid (▪) were determined from the linear best fit of the plotted data. (D) Hill Plot was generated to determine the apparent Km values for each condition.

References

    1. Kyne L, Hamel MB, Polavaram R, Kelly CP (2002) Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile . Clin Infect Dis 34: 346–353. - PubMed
    1. O’Brien JA, Lahue BJ, Caro JJ, Davidson DM (2007) The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 28: 1219–1227. - PubMed
    1. Czuprynski CJ, Johnson WJ, Balish E, Wilkins T (1983) Pseudomembranous colitis in Clostridium difficile-monoassociated rats. Infect Immun 39: 1368–1376. - PMC - PubMed
    1. Reeves AE, Koenigsknecht MJ, Bergin IL, Young VB (2012) Suppression of Clostridium difficile in the gastrointestinal tracts of germfree mice inoculated with a murine isolate from the family Lachnospiraceae. Infect Immun 80: 3786–3794. - PMC - PubMed
    1. Pawlowski SW, Calabrese G, Kolling GL, Platts-Mills J, Freire R, et al. (2010) Murine model of Clostridium difficile infection with aged gnotobiotic C57BL/6 mice and a BI/NAP1 strain. J Infect Dis 202: 1708–1712. - PMC - PubMed

Publication types